The information regarding the European Headache Alliance has been updated in the Transparency Register:
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Their mission is to discover new ways to improve and extend people’s lives. Their vision is to be a trusted leader in changing the practice of medicine.
With synergistic strengths and unique innovation, they offer better healthcare and accessible treatment to millions worldwide.
Teva was established in 1901, their global headquarters are based in Israel.
Number 1 in generics worlwide
120 billion tablets and capsules produced each year
80 number of countries in which they operate worldwide
Pfizer Corporate Responsibility believes that all individuals, everywhere, deserve access to quality healthcare and the opportunity to lead healthy lives. We combine traditional philanthropic methods with novel approaches that create an enduring and meaningful impact on public-health systems to facilitate access to healthcare for under-served communities around the world.
Eli Lilly and Company is an American global pharmaceutical company with headquarters located in Indianapolis, Indiana, in the United States. The company also has offices in Puerto Rico and 17 other countries.
PROMISE : Lilly unites caring with discovery to make life better for people around the world.
MISSION: We make medicines that help people live longer, healthier, more active lives.
VISION : We will make a significant contribution to humanity by improving global health in the 21st century.
VALUES: Integrity, excellence and respect for people.
Curelator Headache guides individuals with migraine headaches to identify their personal triggers, dismiss irrelevant factors, and discover protectors.
The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout, and inflammation.
Their ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company. They are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, they are strongly committed to innovation.